Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
NCT07596121Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- May 2026
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in non-small cell lung cancer (NSCLC), sponsored by Tangdu Hospital. Started May 2026; status: recruiting.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07596121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596121.